NASDAQ:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $1.88 +0.11 (+6.21%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.09 (-4.52%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Propanc Biopharma Stock (NASDAQ:PPCB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$1.65▼$2.0050-Day Range$1.35▼$2.9052-Week Range$1.30▼$270.25Volume1.28 million shsAverage Volume1.95 million shsMarket Capitalization$4.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents. The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth. Propanc has conducted toxicology studies and in vitro assessments to establish safety profiles and enzyme stability, and it continues to advance its candidates through formulation optimization and manufacturing scale-up. In parallel, Propanc explores potential combination regimens with established oncology drugs to support future clinical trial designs. Headquartered in Perth, Western Australia, with additional research collaborations in North America, Propanc Biopharma serves a global oncology community through its development partnerships and licensing discussions. The company is governed by a board and executive team with experience in biotechnology, protein engineering and clinical development, and it aims to position its enzyme-based platform as a complementary approach to existing cancer therapies. AI Generated. May Contain Errors. Read More Propanc Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScorePPCB MarketRank™: Propanc Biopharma scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPropanc Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePropanc Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Propanc Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Propanc Biopharma is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Propanc Biopharma is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPropanc Biopharma has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.64% of the float of Propanc Biopharma has been sold short.Short Interest Ratio / Days to CoverPropanc Biopharma has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Propanc Biopharma has recently increased by 1,029.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPropanc Biopharma does not currently pay a dividend.Dividend GrowthPropanc Biopharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.86 News SentimentPropanc Biopharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Propanc Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for PPCB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Propanc Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders28.50% of the stock of Propanc Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPropanc Biopharma has minimal institutional ownership at this time.Read more about Propanc Biopharma's insider trading history. Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Stock News HeadlinesPropanc Biopharma launches $5M share repurchase programJuly 2, 2026 | msn.comPropanc Biopharma Initiates $5.0 Million Share Repurchase ProgramJuly 2, 2026 | globenewswire.com4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%.July 6 at 1:00 AM | Chaikin Analytics (Ad)Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH StudyJune 16, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH StudyJune 16, 2026 | globenewswire.comPPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?June 13, 2026 | finance.yahoo.comPropanc Biopharma Authorizes $5.0 Million Share Repurchase ProgramJune 11, 2026 | globenewswire.comPropanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, SpainJune 2, 2026 | markets.businessinsider.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $13.4150 at the start of the year. Since then, PPCB stock has decreased by 86.1% and is now trading at $1.8640. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (NASDAQ:PPCB) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($312.50) EPS for the quarter. When did Propanc Biopharma's stock split? Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How will Propanc Biopharma's stock buyback program work? Propanc Biopharma's board authorized a stock buyback plan on Thursday, July 2nd 2026, which allows the company to repurchase $500,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 15,243,902.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued. When did Propanc Biopharma IPO? Propanc Biopharma (PPCB) raised $5 million in an IPO on Friday, August 15th 2025. The company issued 1,000,000 shares at a price of $4.00-$6.00 per share. D. Boral Capital (ex-EF Hutton) and Craft Capital served as the underwriters for the IPO. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH). Company Calendar Last Earnings5/15/2025Today7/06/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PPCB Previous SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year Founded2007Profitability EPS (Trailing Twelve Months)($24.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-151.28% Return on Assets-109.53% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$29.94 per share Price / Book0.06Miscellaneous Outstanding Shares2,280,000Free Float1,629,000Market Cap$4.29 million OptionableNot Optionable Beta3.49 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PPCB) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | SponsoredI Turned $57k Into $1.87MI spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...Decentralized Masters | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
